News

Filter

Current filters:

Jakafi

Incyte earns $60 million milestone on European reimbursement for Jakavi

Incyte earns $60 million milestone on European reimbursement for Jakavi

02-10-2014

US biopharma company Incyte says that it has earned a $60 million milestone payment from Swiss pharma…

BiotechnologyEuropeFinancialIncyteJakafiJakaviNovartisOncologyPricing

Incyte soars on positive mid-stage ruxolitinib trial results

22-08-2013

Shares of US drug developer Incyte Corp (Nasdaq: INCY) leapt 21% to $32.55 in premarket trading yesterday…

IncyteJakafiOncologyPharmaceuticalResearchruxolitinib

First myelofibrosis drug, Novartis' Jakavi, approved in Europe

29-08-2012

Swiss drug major Novartis (NOVN: VX) received approval yesterday from the European Commission for Jakavi…

EuropeIncyteJakafiJakaviNovartisOncologyPharmaceuticalRare diseasesRegulation

COMPANY SPOTLIGHT

Menarini

Back to top